Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, June 21, 2022
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
Jay Olson Maintained (ACAD) at Hold with Decreased Target to $19 on, Jun 21st, 2022
Jay Olson of Oppenheimer, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $23 to $19 on, Jun 21st, 2022.
Jay has made no other calls on ACAD in the last 4 months.
There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Jay's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022
- Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $24 on, Monday, March 7th, 2022
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022
These are the ratings of the 2 analyists that currently disagree with Jay
- Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022
